[1]孙竹清,蔡正生,郑基永.补肾健脾壮骨方联合钙尔奇D治疗脾肾两虚型原发性骨质疏松症的疗效及对CaM、TGF-β1的影响[J].西部中医药,2022,35(09):99-102.[doi:10.12174/j.issn.2096-9600.2022.09.19]
　SUN Zhuqing,CAI Zhengsheng,ZHENG Jiyong.Clinical Effects of Tonifying-kidney-spleen Strengthening-bone Prescription and Caltrate D in the Treatment of Primary Osteoporosis of Spleen-kidney Dual Deficiency Pattern and Its Influence on the Levels of CaM and TGF-β1[J].Western Journal of Traditional Chinese Medicine,2022,35(09):99-102.[doi:10.12174/j.issn.2096-9600.2022.09.19]
点击复制

补肾健脾壮骨方联合钙尔奇D治疗脾肾两虚型原发性骨质疏松症的疗效及对CaM、TGF-β1的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年09期
页码:
99-102
栏目:
临证经验
出版日期:
2022-09-15

文章信息/Info

Title:
Clinical Effects of Tonifying-kidney-spleen Strengthening-bone Prescription and Caltrate D in the Treatment of Primary Osteoporosis of Spleen-kidney Dual Deficiency Pattern and Its Influence on the Levels of CaM and TGF-β1
作者:
孙竹清, 蔡正生, 郑基永
沈阳市骨科医院，辽宁 沈阳 110044
Author(s):
SUN Zhuqing, CAI Zhengsheng, ZHENG Jiyong
Shenyang Orthopedic Hospital, Shenyang 110044, China
关键词:
原发性骨质疏松症; 脾肾两虚; 钙调素、转化生长因子; 补肾健脾壮骨方; 临床疗效
Keywords:
primary osteoporosis; spleen-kidney dual deficiency; CaM; TGF-; tonifying-kidney-spleen strengthening-bone prescriptionclinical effects
分类号:
R274.9
DOI:
10.12174/j.issn.2096-9600.2022.09.19
摘要:
目的探讨补肾健脾壮骨方联合钙尔奇D治疗脾肾两虚型原发性骨质疏松症的临床疗效及对血清钙调素（calmodulin，CaM）、转化生长因子β1（transforming growth factor-β1,TGF-β1)水平的影响。 方法将脾肾两虚型原发性骨质疏松症患者108例按随机数字表法分为对照组和试验组各54例，对照组予六味地黄丸联合钙尔奇D片，试验组予补肾健脾壮骨方联合钙尔奇D片，两组均治疗6个月后观察患者临床疗效、中医证候积分、腰椎L2～4及双侧股骨颈骨密度、血液流变学指标与血清CaM、TGF-β1水平。 结果试验组总有效率为94.12%，高于对照组的80.77%（P＜0.05）；治疗后中医证候积分试验组总评分低于对照组（P＜0.05），其中腰脊酸痛、腰膝酸软、肢体倦怠评分低于对照组（P＜0.05），而头晕目眩评分两组相比差异无统计学意义（P＞0.05）；治疗后试验组患者腰椎、双侧股骨颈骨密度高于对照组（P＜0.05），血浆黏度、红细胞聚集指数及血清TGF-β1水平低于对照组（P＜0.05），CaM水平高于对照组（P＜0.05）。 结论补肾健脾壮骨方联合钙尔奇D能够防止脾肾两虚型原发性骨质疏松症患者骨密度下降，改善血液流变性及骨代谢指标，效果优于六味地黄丸联合钙尔奇D。
Abstract:
ObjectiveTo discuss clinical effects of tonifying-kidney-spleen strengthening-bone prescription (TKSSBP) and caltrate D in the treatment of primary osteoporosis of spleen-kidney dual deficiency pattern and its influence on the levels of CaM and TGF-β1. MethodsAll 108 patients were allocated to the control group and the experiment group by using random number table method, with 54 cases in each group, the control group was given Liuwei Dihuang pills and caltrate D, and the experiment group TKSSBP and caltrate D, both groups were treated for six months, to observe clinical effects, TCM syndrome integrals, bone mineral density (BMD) of lumbar vertebra L2~L4 and bilateral femoral necks, hemorheology indexes and the levels of serum CaM and TGF-β1 between both groups. ResultsTotal effective rate of the experiment group was 94.12%, higher than 80.77% of the control group (P<0.05); total scores of TCM syndrome integrals of the experiment group were lower than these of the control group (P<0.05), among which, the scores of lumbar and spinal ache, soreness and weakness of waist and knees were lower than these of the control group (P<0.05), while the difference had no statistical meaning in the scores of light-headedness between both groups (P>0.05); the experiment group was higher than the control group in BMD of lumbar vertebra and bilateral femoral necks (P<0.05); the experiment group was lower than the control group in plasma viscosity, erythrocyte aggregation index and the levels of TGF-β1 (P<0.05), higher than the control group in the levels of CaM (P<0.05). ConclusionTKSSBP and caltrate D in the treatment of primary osteoporosis of spleen-kidney dual deficiency pattern could prevent the decrease of BMD, improve hemorheology indexes and bone metabolism indexes, and its effects are superior to these of Liuwei Dihuang pills and caltrate D.

相似文献/References:

[1]曾昭洋,胡文斌,魏学玲,等.中老年人原发性骨质疏松症与中医体质类型的Logistic回归分析[J].西部中医药,2018,31(02):66.
　ZENG Zhaoyang,HU Wenbin,WEI Xueling,et al.Logistic Regression Analysis of Middle-aged and Elderly People with Primary Osteoporosis and TCM Constitution Types[J].Western Journal of Traditional Chinese Medicine,2018,31(09):66.

备注/Memo

备注/Memo:
孙竹清（1977—），男，硕士学位，副主任医师。研究方向：综合外科。辽宁省自然科学基金（2014020186，2015020567）。
更新日期/Last Update: 2022-10-08